Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems

Glück, Reinhard; Metcalfe, Ian C

doi:10.1016/s0264-410x(02)00567-4

Cited by 28 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Virosomes were not only found suitable and versatile carrier molecules as vaccines against the parental virus, but further exploited as carrier systems for unrelated vaccine antigens, nucleic acids and drugs. The most advanced virosomal systems for targeted delivery and release are the immunopotentiating reconstituted influenza virosomes (IRIVs), which are based on the envelope proteins of influenza virus [113]. Virosomes have the same versatility with regard to lipid composition as liposomes, and antigens can be included in virosomal vaccine formulations through direct incorporation into membrane, adsorption to the virosomal surface, chemical coupling to a hydrophobic anchor or encapsulation inside the vesicle.…”

Section: Virosomes: a Versatile Carrier Systemmentioning

confidence: 99%

Vaccination Strategies against Malaria: novel carrier(s) more than a tour de force

Tyagi

Garg

Sahu

2012

Journal of Controlled Release

View full text Add to dashboard Cite

Section: Virosomes: a Versatile Carrier Systemmentioning

confidence: 99%

Vaccination Strategies against Malaria: novel carrier(s) more than a tour de force

Tyagi

Garg

Sahu

2012

Journal of Controlled Release

View full text Add to dashboard Cite

“…These virosomal systems are also referred as immunopotentiating reconstituted influenza virosomes (IRIVs) with a mean diameter of approximately 150 nm and have 15 nm projections from the surface. As soon as the antigen is delivered, virosomes gets degraded completely within the cells .…”

Section: Delivery Systems Used In Mucosal Vaccinationmentioning

confidence: 99%

Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles

Srivastava

Gowda

Madhunapantula

et al. 2015

APMIS

View full text Add to dashboard Cite

Mucosal immune responses are the first-line defensive mechanisms against a variety of infections. Therefore, immunizations of mucosal surfaces from which majority of infectious agents make their entry, helps to protect the body against infections. Hence, vaccinization of mucosal surfaces by using mucosal vaccines provides the basis for generating protective immunity both in the mucosal and systemic immune compartments. Mucosal vaccines offer several advantages over parenteral immunization. For example, (i) ease of administration; (ii) non-invasiveness; (iii) high-patient compliance; and (iv) suitability for mass vaccination. Despite these benefits, to date, only very few mucosal vaccines have been developed using whole microorganisms and approved for use in humans. This is due to various challenges associated with the development of an effective mucosal vaccine that can work against a variety of infections, and various problems concerned with the safe delivery of developed vaccine. For instance, protein antigen alone is not just sufficient enough for the optimal delivery of antigen(s) mucosally. Hence, efforts have been made to develop better prophylactic and therapeutic vaccines for improved mucosal Th1 and Th2 immune responses using an efficient and safe immunostimulatory molecule and novel delivery carriers. Therefore, in this review, we have made an attempt to cover the recent advancements in the development of adjuvants and delivery carriers for safe and effective mucosal vaccine production.

show abstract

“…Virosomal vaccines are reconstituted virus envelopes that, after DC uptake and fusion with the endosomal membrane, deliver viral proteins into the cytoplasm, the peptides from which are loaded onto MHC I to stimulate CTLs (reviewed in [83]). Virosomal influenza vaccines containing HA, currently marketed in Europe, have also shown similar serologic responses to conventional split-virus vaccines in older adults, but potentially with increased tolerability to other adjuvanted split-virus vaccines [84].…”

Section: Advances In Vaccine Technology and Deliverymentioning

confidence: 99%

Influenza Vaccination in the Elderly: Seeking New Correlates of Protection and Improved Vaccines

McElhaney

2008

Aging Health

View full text Add to dashboard Cite

Influenza is foremost among all infectious diseases for an age-related increase in risk for serious complications and death. Determining the benefit of current influenza vaccines is largely limited to epidemiologic studies, since placebo-controlled trials of influenza vaccines are no longer considered ethical in the older adult population. Vaccine effectiveness is calculated from the relative reduction in influenza outcomes in individuals who elect to be vaccinated compared with those who do not, the assumptions for which are diverse and have led to considerable controversy as to the exact benefit of influenza vaccination in older adults. In spite of this controversy, there is no doubt that new influenza vaccine technologies are needed to improve protection and reverse the trend of rising hospitalization and death rates related to influenza in older adults despite widespread influenza vaccination programs. This article will review the challenges to new vaccine development, explore the potential correlates of protection against influenza, and describe how new vaccine technologies may improve protection against complicated influenza illness in the older adult population.

show abstract

Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems

Cited by 28 publications

References 16 publications

Vaccination Strategies against Malaria: novel carrier(s) more than a tour de force

Vaccination Strategies against Malaria: novel carrier(s) more than a tour de force

Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles

Influenza Vaccination in the Elderly: Seeking New Correlates of Protection and Improved Vaccines

Contact Info

Product

Resources

About